PhaseBio Pharmaceuticals, Inc.
ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE

Abstract:

The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The disclosure provides improved pharmacokinetics for peptide and small molecule drugs.